Purpose of Review This paper provides a narrative review of the co-use of alcohol and opioids, and its impact on biological, neurocognitive, and behavioral systems. In addition, data addressing co-use among patients receiving opioid replacement therapy and those who have chronic pain are discussed. Recent Findings Alcohol and opioids are among the most commonly used substances, and co-use has contributed to a growing number of accidental poisonings, emergency room visits, and overdose deaths. Prevalence of co-use is high among multiple populations and severely impacts treatment outcomes. Summary Treatment for those that co-use alcohol and opioids is inadequate. Future research should further investigate salient influences on co-use and identify potential targets for intervention to address this treatment need.
Introduction
Alcohol and prescribed opioids represent two of the most commonly used substances in the USA. Among individuals aged 12 or older, more than 50% reported current alcohol use in 2015. Opioids are the most frequently used prescription medication [1] with approximately 20% of individuals with pain-related diagnoses prescribed opioids in 2010 [2] . Given that both substances are commonly used, are both central nervous system depressants [3] , and have synergistic effects [4] , their co-use presents a substantial risk factor for morbidity (i.e., overdose) and mortality. Unfortunately, co-use appears to be relatively common in some settings with recent data indicating that 19% of emergency department visits and 22% of overdose deaths involved both opioids and alcohol [5] . Further, prescription opioids and alcohol are the most common substances found in accidental poisonings [6] .
The purpose of the present review is to synthesize the literature concerning the co-use of alcohol and opioids. Following an overview of the biological mechanisms that are shared by the two substances, findings regarding the prevalence, neurocognitive and behavioral impacts, and salient risk factors in relation to co-use will be discussed. In addition, co-use of alcohol and opioids in two special clinical populations will be reviewed, including those receiving opioid substitution therapy (e.g., methadone maintenance) and those with chronic pain who are prescribed opioids as part of their treatment regimen.
Biological Mechanisms Shared by Alcohol and Opioids
When discussing the use of two or more substances, simultaneous use refers to the co-ingestion of substances at the same time (e.g., within 2 h of one another), while concurrent use refers to co-use within a broader time period (e.g., 12 months) [7, 8••] . At a biological level, when used together, alcohol and opioids interact in two ways. First, they can interact through pharmacokinetic interactions, in which alcohol and opioids interfere with the metabolization of one another. Second, alcohol and opioids can interact through pharmacodynamic interactions, in which they each enhance the effect of one another (see Kreek 1984 and Weathermon & Crabb 1999 for detailed reviews) [3, 9] . These interactions arise as both alcohol and opioids require, and therefore compete for, liver enzymes in order to be metabolized. The competition for enzymes result in the pharmacokinetic interactions (i.e., an increase in metabolism speed) to account for the amplified load on the body and the increase in metabolism speed then produces many of the additive effects through the pharmacodynamic interactions [9] . The primary concern with co-use is that both opioids and alcohol act as central nervous system (CNS) depressants and use of both substances at the same time can produce significant respiratory depression and sedation, common contributors to fatal overdoses [4] . Risk for overdose is also increased with certain prescription opioid formulations, specifically high dose, prolonged release, and once daily formulations, when combined with alcohol [10] .
Prevalence of Co-use
Co-use of opioids and alcohol appears to be relatively common. For example, Peacock and colleagues (2016) [11] found that upwards of 20% of individuals prescribed opioids consume alcohol and opioids in the same day, with a median of 4.6 drinks [11] . A similar proportion of co-use was reported in a sample of just over 1500 individuals in Australia who were daily users of prescribed opioids with 16% classified as "occasional" and 8% as "regular" risky drinkers, defined as the consumption of more than four standard drinks, on an at least yearly or weekly basis, respectively [12] . In a prevalence study of simultaneous use specifically, one in eight patients receiving chronic opioid therapy reported the ingestion of two or more drinks within 2 h of taking an opioid dose [13] .
In those who use opioids non-medically, prevalence rates of co-use appear even higher, with 50-70% reporting simultaneous ingestion in the past year [8••, 14] . Data also suggest that individuals who meet criteria for Alcohol Use Disorder (AUD) are 18 times more likely to report a prescription drug use disorder and non-medical use of prescription medications than those who did not meet criteria for AUD [15] . Conversely, prevalence of AUD was found to be significantly higher among individuals on a high potency opioid regimen than the general population [10] .
Neurocognitive Impacts of Co-use
Substantative neurocognitive effects have been found both when using these substances simultaneously and concurrently. Consistent with respiratory depression findings, simulateous use is associated with short-term decreases in oxygen saturation, which often precedes impairments in hand-eye coordination as well as short-and long-term memory recall [16] . Research examining chronic alcohol and opioid use has identified multiple neurocognitive deficits; however, these findings should be interpreted with caution, as temporal precendent has not yet been fully addressed in the current neurocognitive literature. Generally, concurrent use has been associated with impairment in executive functioning, attentional focus, working memory tasks, and motor functioning [17] . A meta-analysis by Baldacchino et al. (2012) compared neurocognitive functioning among individuals with chronic opioid use (excluding those with alcohol dependence) to healthy controls and found that individuals exhibited deficiencies in verbal working memory, cognitive impulsivity, and cognitive flexibility. Although individuals with alcohol dependence were excluded from the Baldacchino et al. (2012) study, previous research shows that with the addition of alcohol, these impairments become worse [18•, 19, 20] . In addition, to help address issues of temporal precendence, Baldacchino et al. (2012) compared these deficits to longterm heroin users (>6 months) and determined that core deficits were found in verbal fluency and working memory, and opioid-specific effects in divided attention, reasoning, and decision-making. Although not conclusive, these findings suggest that individuals may have fewer cognitive resources that could impede adherence and engagement with medical and psychological treatments as a result of co-use.
Behavioral Impacts of Co-use
In addition to the harmful neurocognitive effects, co-use use is also associated with increased substance use and a number of other poor health outcomes. For example, among college students, it was found that simultaneous users consumed alcohol more frequently and in higher amounts than those who used only alcohol [21] . It has also been found that those who had co-ingested in the past had significantly more substance use related problems than those who did not co-ingest, even after controlling for frequency of alcohol and drug use [14] . Simultaneous users exhibited much more aberrant drug behaviors, such as requesting early refills, motor vehicle accidents, and hoarding medication, as well as lower treatment completion rates than single substance users [22, 23] . Data suggests that any use of alcohol and opioids can increase risk for substance use disorders and recurrence of depressive, anxiety, and bipolar episodes [7, 24, 25] . A study done by Hedden et al. (2010) found that among the general population, past year concurrent alcohol and opioid use was associated with poorer mental health outcomes, unemployment, and incarceration. Findings also indicated that alcohol dependence was associated with other comorbid substance dependence 64% of the time, with prescription opioids being the second most common substance behind marijuana [26] . Another national survey found that 60% of individuals with a past year prescription opioid use disorder met criteria for another past year substance use disorder, with alcohol being the most common substance [15] .
In experimental settings, concurrent use of alcohol and opioids has been associated with a diversity of adverse effects, including vomiting, lightheadedness, dizziness, drowsiness, dry mouth, headaches, and nausea [27] , with significantly more pronounced dysphoric effects on women. Repeated or prolonged co-use has also been examined as a risk factor for long-term complications. In addition to increased risk for liver disease and degradation of brain tissue [16, 27] , alcohol can negatively affect the binding properties of opioid receptors, leading to a decreased effect of exogenous opioids [28] . This effect not only puts the co-user at risk for experiencing increased pain but could also contribute to additional use of opioids to achieve adequate pain reduction and thereby increase risk of overdose.
Risk Factors and Patterns of Co-use
Given the sparse literature on co-use, there is currently only limited information with regard to risk factors for co-use. The data does indicate that those meeting criteria for Major Depression Disorder, Generalized Anxiety Disorder, and chronic pain report higher rates of concurrent use in the past year [22, 24, 26, 29•] . Engaging in deviant behaviors (e.g., stealing, selling illegal drugs), initiating alcohol use at an earlier age, and reporting a sexually transmitted infection were also associated with concurrent use [8••, 26] . In addition, individuals identifying as White, male, and younger age are 2-5 times more likely to report non-medical prescription drug use in the past year [25] . Particularly, research examining substance use in young adults has found young adults are at a much higher risk for reporting binge drinking, AUD's, and non-medical use of prescription opioids than older adults. Moreover, of those young adults who met criteria for AUD, 3 in 10 reported significant non-medical use of opioids [25] .
Although a clear link between alcohol and opioid use has been established, the literature has produced mixed findings in regard to the relationship between patterns of use with opioids and alcohol. Specifically, regarding the validity of the "substitution hypothesis," which states that opioids and alcohol patterns of use have an inverse relationship [3, 4] , mixed findings have emerged with some studies supporting this hypothesis [23, 30] and others finding is that opioid use increased with alcohol consumption [31, 32] . A recent meta-analysis indicated inconclusive support for the substitution hypothesis but did find conclusive support that alcohol significantly increased relapse to drug use [33] . When taken together, these findings may reflect the poor efficacy of addiction treatments when dealing with dual substance users.
Co-use Among Special Populations Patients Receiving Opioid Substitution Therapy
Due to the rising number of individuals struggling with opioid addiction, there has also been a rise in number of patients seeking opioid substitution treatment, including methadone and buprenorphine. For a review of efficacy of these opioid substitution therapies, please see Whelan and Remski (2012) [34] . Generally, methadone is a full-agonist treatment, meaning that it most closely mimics heroin by producing high intrinsic activity among μ opioid receptors, causing similar euphoric effects, but also decreasing withdrawal and craving symptoms. Buprenorphine is a partial-agonist treatment, meaning that it has low intrinsic activity among μ opioid receptors, causing less analgesic and euphoric effect, but still decreasing withdrawal and craving symptoms [34] . Both treatments also limit the effect of other exogenous opioids [35] . Due to the strong relationship exhibited between alcohol and opioid use, alcohol is often used among individuals receiving opioid substitution therapies, with prevalence rates indicating that one third of patients receiving opioid substitution treatment also qualify for concurrent alcohol misuse [36••] .
Few studies, however, have examined the effect of alcohol when used concurrently with opioid-agonists among humans. Previous studies done in rat models have provided evidence that acute alcohol consumption increases peak methadone plasma concentration, while chronic alcohol consumption reduces peak methadone plasma levels [36••] . A study done with humans by Clark, Dietze, Lenné, and Redman (2006) examined the effect of alcohol among 40 patients receiving either methadone or buprenorphine and assessed the administration of one alcohol dose in two separate sessions (2-3 h before opioid dose vs 1-2 h after opioid dose) [35] . The interaction between alcohol and opioids was the strongest during peak opioid plasma levels, 2-3 h after receiving their opioid substitution treatment. Patients reported greater sedation and feelings of euphoria, and those who received methadone reported these symptoms at a greater intensity than those receiving buprenorphine [35] . The substitution hypothesis among this population has also had mixed findings with most studies finding no change in alcohol consumption once opioid substitution treatment is started [37] .
It is well known that alcohol use is a risk factor for poorer treatment outcomes and compliance with pharmacological treatments, and this still holds true for patients on opioid substitution therapies [38] . In addition, drug-related deaths are also high among this population with one study indicating that 44% of deaths were related to drug and alcohol overdoses, and another study finds that excessive alcohol use was the leading contributor to death among active methadone maintenance patients [39, 40] . Previous research also shows that methadone maintenance patients that meet criteria for an AUD were less satisfied on their dose of methadone, even though they had significantly higher doses, than those who did not meet criteria for AUD [41] . This same study also found that those who met criteria for AUD reported significantly more physical and psychological health problems along with poorer quality of life and social functioning [41] . Again, these findings highlight the need for more robust and efficacious addiction treatment programs that can better address dual substance users, even among patients receiving opioid substitution therapies.
Chronic Pain Patients
Individuals engaging in the concurrent use of alcohol and opioids who also have chronic pain have an increased complexity surrounding their use of substances and their treatment needs. For example, chronic pain patients that use opioids and alcohol concurrently have been found to utilize medical treatments more frequently, report significantly more health problems, and have poorer treatment outcomes than those who do not co-use [42, 43] . For example, a 12-month longitudinal study of veterans enrolled in outpatient addiction treatment programs found that those with persistent pain, as compared to intermittent pain, were in treatment for 35 fewer days (indicating lower levels of engagement with treatment and/or dropout), less likely to abstain from drugs or alcohol, and more likely to be hospitalized, leading to higher total service costs [42] . Research has also shown that individuals with persistent pain are at a much higher risk for developing a substance use disorder, relapse during substance abuse treatment, and engagement in aberrant pain management behaviors [29•, 44, 45] .
Addiction treatment outcomes are poor among chronic pain patients as alcohol is often used to help manage their pain and other related symptoms in addition to using prescription opioids [42, 46] . Thus, it is often unclear whether it is best to treat the substance use first, the pain first, or address both issues concurrently [44, 45, 47] . A national survey of 5692 individuals in the USA with substance use disorder and pain indicated that 58% reported the substance use disorder occurred first, 35% reported the pain occurred first, and 7% indicated they both occurred within the same year [48] . Evidence has also shown that pain transmission and alcohol reinforcement often have similar and overlapping neural substrates, therefore further increasing hardship for concurrent users in addiction treatment [49] . However, interestingly, Savage (1993) notes that often after patients have been weaned off both alcohol and opioids and completed addiction treatment, pain often goes unchanged or even decreases, but rarely increases [46] . In addition, a recent study asked treatment-seeking individuals with opioid dependence about their reasons for concurrent use and found that many initially used concurrently to help manage pain; however, at the time of the interview, these individuals were only using alcohol and opioids concurrently to avoid withdrawal symptoms [50] . Given these data, it seems clear that pain and substance use exacerbate eachother, and that substance use treatment programs may not be adequate to address their needs.
Conclusion
Based on the extant literature, it can be concluded that co-use of alcohol and opioids is a reliable risk factor for a variety of poor health outcomes. Specifically, co-use is consistently associated with increased risk of overdose and death, as well as a diffuse set of cognitive deficits, greater frequency of mental health diagnoses, poorer adherence to treatment, and more frequent discontinuation of treatment. Further, those who couse these two substances appear to use them with greater frequency and/or in larger amounts in comparison to those who do not co-use. Thus, the risks of co-use are readily identifiable across the broader array of studies, as well as in those who are on opioid substitution therapy or who are diagnosed with chronic pain.
There is, however, a clear need for guidance regarding effective interventions for such risky co-use. There is no current literature on how best to address the co-use of alcohol and opioids specifically, and there is limited data on the efficacy of treatments for polysubstance use. A meta-analysis done by Dutra et al. (2008) did examine the efficacy of four substance use treatments among individuals who used one of four substances (cannabis, cocaine, opioids, or polysubstance [51••] . It was found that polysubstance users were the least responsive to treatment (intervention effect size, d = 0.24), followed by opioid users (d = 0.39). By comparison, the effect sizes were larger for cocaine users (d = 0.62) and cannabis users (d = 0.81). Therefore, findings suggest that current treatment outcomes for co-use of alcohol and opioids are likely to be weak, as compared to treatment of other substances. However, given that the data only spans until 2005, it is possible that treatment outcomes have improved. For example, one relatively new treatment that has shown promise in polysubstance users is Mindfulness Based Relapse Prevention (MBRP). Studies using MBRP have found significant decreases in alcohol and drug use among polysubstance users [52] [53] [54] . Regardless, the current literature does not provide clear empirically based guidance on appropriate interventions or what the components of effective interventions are likely to be for those who co-use alcohol and opioids. Given the prevalence of co-use and the significant adverse impacts associated with it, there is a clear need for further work in this area to identify appropriate and efficacious interventions.
Furthermore, while the treatment literature for other polysubstance treatment approaches is likely relevant to alcohol and opioid co-use, there are likely unique aspects involved in treatments concerning two substances that can be legally obtained or which involve those who are prescribed opioids as part of their pain treatment regimen. These distinctions would appear to require focused efforts to determine the salient influences on co-use, effects that are maintaining this use, and appropriate areas for intervention.
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